turnaround track
earn report post-cal follow-up well receiv
march share rose vs think
stock trade well part owe guidanc robust yet
conserv also due detail regard account oversight
auditor opinion express ernst young
file told us done great job
intent switch auditor addit continu make
progress clear materi weak intern control
regard incom tax process possibl weak
clear interim basi time result
report happen would expect investor entir
focus turnaround appear track
perrigo guidanc reason conserv view
guid sale vs sale estim vs
prior estim adjust ep vs
estim unchang revis sale estim primarili due
less fx translat consum healthcar intern chci vs
prior us fundament noth chang februari
initi piec diamond rough comfort
above-guid ep estim exhibit page detail
segment guidanc achiev view expect
consum healthcar america chca sale approxim
consum healthcar intern chci sale
rx gener sale disclos
segment growth expect within /- growth rate
estim call growth chca chci rx
within rang chca chci mainli
base fx model base spot rate hold go forward
rx primarili think risk-adjust gener proair
told us gener proair approv launch
capac launch perrigo/catal partner
proair receiv three complet respons letter crl
proair abbrevi new drug applic anda recent late
tell us fda concern address latest
submiss howev comfort risk-adjust estim
price target base discount cash flow termin
multipl method discount rate vs prior termin
ev/ebitda multipl
chang made note
price target usd chang
buy chang
page analyst certif
perform rel
co plc engag product
over-the-count consum good
profit loss summari
growth margin
domin share privat label store brand
market solid presenc european brand over-the-counter
chca busi benefit renew regulatori
legisl focu over-the-counter
account oversight improv
chci busi stabil look pois growth
rx busi proven resili
challeng extern oper margin stabil low
recent hire new ceo uwe rhrhoff track
record effici oper typic deliv
promis think knowledg eu market help
continu success turnaround chci busi
valu use discount cash flow model base
fcff discount rate termin ev/ebitda
multipl
chang net debt
average cost debt
risk invest thesi
monograph reform bill pass could neg
impact assumpt increas innov penetr
over-the-counter medicin true fda act find
way eas rx-to-otc pathway risk thesi
includ increas competit gener pressur rx
busi expect turnaround eu stall
regulatori risk price risk litig risk busi
exhibit think perrigo guidanc conserv
express million unless otherwis note
note bcm estim assum repurchas approxim share opportunist share repurchas
author origin approv board director octob approxim remain estim
compani report factset consensu march market close bcm estim
exhibit fine-tun ep estim
compani report factset consensu march market close bcm estim
price target base discount cash flow termin multipl
method discount rate vs prior fine-tun discount rate
due recent increas volatil equiti termin ev/ebitda multipl
main risk thesi relat view regul legisl
regulatori legisl solut implement reduc
prescript drug cost inflat includ increas access non-prescript drug
posit impact think assumpt model
call acceler fundament may optimist risk thesi
includ increas competit gener pressur perrigo rx busi
expect turnaround eu stall regulatori risk price risk litig
risk busi develop risk among other
profit loss account
million unless otherwis note
sale
sale
sale
sale
sale
sale
sale
total expens
total expens
total expens
total expens
sale
sale
 year
reconcili gaap
reconcili gaap
reconcili gaap
reconcili gaap
million unless otherwis note
cash equival
prepaid expens
properti plant equip net
goodwil
payrol relat tax
accumul incom loss
total liabil equiti
total liabil equiti
total liabil equiti
total liabil equiti
million unless otherwis note
depreci amort
loss acquisition-rel fx
chang financi asset
tysabri chang fair valu
incom tax benefit stock option
excess tax benefit stock transact
loss sale invest
loss sale busi
loss extinguish debt
loss equiti method invest
amort debt discount premium
chang work capit
chang work capit
chang work capit
chang work capit
payrol relat tax
total chang work capit
oper activ
oper activ
oper activ
oper activ
acquisit busi
proce royalti right
settlement acquisition-rel fx
acquisit intang asset
addit properti equip
proce sale secur
proce sale pp
proce sale tysabri
proce sale busi
invest activ
invest activ
invest activ
invest activ
purchas non-controlling interest
repay long-term debt
borrow repay revolv
proce debt issuanc
premium earli retir debt
share withheld tax liabil
excess tax benefit stock transact
issuanc common stock
equiti issuanc
repurchas common stock
settlement conting consider
financ activ
financ activ
financ activ
financ activ
effect exchang rate cash
net chang cash
begin cash equival
end cash equival
end cash equival
end cash equival
end cash equival
capital-expenditure sale
